Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
This report describes phase 1 clinical trials performed to assess interactions of oral isavuconazole at the clinically targeted dose (200 mg, administered as isavuconazonium sulfate 372 mg, 3 times a day for 2 days; 200 mg once daily [QD] thereafter) with single oral doses of the cytochrome P450 (CYP) substrates: bupropion hydrochloride (CYP2B6; 100 mg; n = 24), repaglinide (CYP2C8/CYP3A4; 0.5 mg; n = 24), caffeine (CYP1A2; 200 mg; n = 24), dextromethorphan hydrobromide (CYP2D6/CYP3A4; 30 mg; n = 24), and methadone (CYP2B6/CYP2C19/CYP3A4; 10 mg; n = 23). Compared with each drug alone, coadministration with isavuconazole changed the area under the concentration‐time curves (AUC∞) and maximum concentrations (C max) as follows: bupropion, AUC∞ reduced 42%, C max reduced 31%; repaglinide, AUC∞ reduced 8%, C max reduced 14%; caffeine, AUC∞ increased 4%, C max reduced 1%; dextromethorphan, AUC∞ increased 18%, C max increased 17%; R‐methadone, AUC∞ reduced 10%, C max increased 3%; S‐methadone, AUC∞ reduced 35%, C max increased 1%. In all studies, there were no deaths, 1 serious adverse event (dextromethorphan study; perioral numbness, numbness of right arm and leg), and adverse events leading to study discontinuation were rare. Thus, isavuconazole is a mild inducer of CYP2B6 but does not appear to affect CYP1A2‐, CYP2C8‐, or CYP2D6‐mediated metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., Bow, E. J., Rahav, G., Neofytos, D., Aoun, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01159-9 · Cited by 1,001
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent
Miceli, M. H., & Kauffman, C. A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ571 · Cited by 338
Azie, N., Neofytos, D., Pfaller, M., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.06.012 · Cited by 222
Epidemiology of invasive fungal diseases on the basis of autopsy reports
Dignani, M. C. (2014) · F1000Prime Reports · doi:10.12703/p6-81 · Cited by 73
Research works printed but not linked: 37
- 10.1126/scitranslmed.3004404 · DOI · Paper page
- 10.1002/phar.1652 · DOI · Paper page
- Alcazar‐Fuoli L, 2012, Ergosterol biosynthesis in Aspergillus fumigatus: its relevance as an antifungal target and role in antifungal drug resistance, Front Microbiol, 3, 439
- 10.1586/14787210.2015.990382 · DOI
- 10.1016/S1473-3099(16)00071-2 · DOI · Paper page
- 10.1002/cpdd.280 · DOI
- 10.1002/cpdd.284 · DOI
- 10.1002/cpdd.285 · DOI
- Hesse LM, 2000, CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants, Drug Metab Dispos, 28, 1176
- 10.1046/j.0306-5251.2003.01862.x · DOI · Paper page
- 10.1073/pnas.86.20.7696 · DOI · Paper page
- 10.1016/0378-4347(95)00574-9 · DOI
- 10.1016/j.bcp.2015.03.007 · DOI
- 10.1097/ALN.0b013e3182423478 · DOI
- 10.1016/j.clpt.2004.05.003 · DOI · Paper page
- 10.1124/dmd.113.053991 · DOI
- 10.1016/j.drugalcdep.2008.12.009 · DOI
- 10.1002/cpdd.137 · doi:10.1002/cpdd.137
- 10.1002/chir.10303 · DOI · Paper page
- 10.1097/ALN.0b013e3181642938 · DOI · Paper page
- 10.1002/jcph.1 · DOI · Paper page
- 10.1097/00008571-199404000-00004 · doi:10.1097/00008571-199404000-00004
- Gaedigk A, 1991, Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism, Am J Hum Genet, 48, 943
- 10.1016/0014-5793(96)00779-X · DOI · Paper page
- 10.1016/S0378-1119(98)00567-8 · DOI
- 10.1046/j.1365-2125.1996.00489.x · doi:10.1046/j.1365-2125.1996.00489.x
- 10.1093/hmg/4.12.2251 · DOI
- 10.1097/00008571-199610000-00005 · doi:10.1097/00008571-199610000-00005
- 10.1111/j.1476-5381.2009.00430.x · DOI · Paper page
- 10.1016/j.clpt.2005.01.018 · DOI · Paper page
- 10.1177/000456329903600604 · DOI
- 10.1128/AAC.00559-06 · DOI
- 10.1016/j.ejps.2004.01.005 · DOI · Paper page
- 10.1177/0091270003253704 · DOI
- 10.1177/0091270006293753 · DOI · Paper page
- 10.1128/AAC.01123-08 · DOI
- 10.1124/dmd.107.019000 · DOI
Cited by
Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption
Nehlig, A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014407 · Cited by 632
Inhibition and induction of CYP enzymes in humans: an update
Hakkola, J., Hukkanen, J., Turpeinen, M., & Pelkonen, O. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02936-7 · Cited by 418
Grzegorzewski, J., Bartsch, F., Köller, A., & König, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.752826 · Cited by 108
Antifungal Drugs TDM: Trends and Update
Kably, B., Launay, M., Derobertmasure, A., Lefeuvre, S., Dannaoui, E., & Billaud, E. M. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000952 · Cited by 81
Shebley, M., Polepally, A. R., Nader, A., Ng, J. W., Winzenborg, I., Klein, C. E., Noertersheuser, P., Gibbs, M. A., & Mostafa, N. M. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00840-7 · Cited by 68
Metadata
- Authors
- Yamazaki, T., Desai, A., Goldwater, R., Han, D., Howieson, C., Akhtar, S., Kowalski, D., Lademacher, C., Pearlman, H., Rammelsberg, D., & Townsend, R.
- Venue
- Clinical Pharmacology in Drug Development
- Publisher
- Wiley
- Published
- 2016-07-15
- Volume
- 6
- Issue
- 1
- Pages
- 54-65
- ISSN
- 2160-763X (ISSN-L)
- 2160-7648
- OpenAlex
- W2411893516
- Cited by
- 42
- References
- 4
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.